TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL

The therapeutic potential of targeting CD19 in B cell malignancies has garnered attention in the past decade, resulting in the introduction of novel immunotherapy agents. Encouraging clinical data have been reported for T cell-based targeting agents, such as anti-CD19/CD3 bispecific T-cell engager b...

Descripción completa

Detalles Bibliográficos
Autores principales: Malik-Chaudhry, Harbani K., Prabhakar, Kirthana, Ugamraj, Harshad S., Boudreau, Andrew A., Buelow, Benjamin, Dang, Kevin, Davison, Laura M., Harris, Katherine E., Jorgensen, Brett, Ogana, Heather, Pham, Duy, Schellenberger, Ute, Van Schooten, Wim, Buelow, Roland, Iyer, Suhasini, Trinklein, Nathan D., Rangaswamy, Udaya S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023237/
https://www.ncbi.nlm.nih.gov/pubmed/33818299
http://dx.doi.org/10.1080/19420862.2021.1890411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023237/
https://www.ncbi.nlm.nih.gov/pubmed/33818299
http://dx.doi.org/10.1080/19420862.2021.1890411

Ejemplares similares